Cetera Investment Advisers Decreases Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)

Cetera Investment Advisers lessened its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 10.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,637 shares of the medical research company's stock after selling 9,312 shares during the period. Cetera Investment Advisers' holdings in Exact Sciences were worth $4,643,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Asset Planning Inc acquired a new position in shares of Exact Sciences in the 4th quarter valued at $40,000. AlphaQuest LLC increased its position in shares of Exact Sciences by 22,825.0% in the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company's stock valued at $52,000 after acquiring an additional 913 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of Exact Sciences in the 4th quarter valued at $66,000. Ostrum Asset Management increased its position in shares of Exact Sciences by 28.4% in the 4th quarter. Ostrum Asset Management now owns 2,382 shares of the medical research company's stock valued at $134,000 after acquiring an additional 527 shares during the period. Finally, Naviter Wealth LLC acquired a new position in shares of Exact Sciences in the 4th quarter valued at $207,000. Hedge funds and other institutional investors own 88.82% of the company's stock.

Wall Street Analyst Weigh In

EXAS has been the topic of several research reports. Barclays upped their target price on Exact Sciences from $55.00 to $75.00 and gave the company an "overweight" rating in a research report on Friday, May 2nd. Scotiabank increased their price target on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 24th. Bank of America cut their price target on Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research report on Thursday, February 20th. William Blair reaffirmed an "outperform" rating on shares of Exact Sciences in a research report on Thursday, February 20th. Finally, Robert W. Baird increased their price target on Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Two equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Exact Sciences presently has an average rating of "Moderate Buy" and an average price target of $70.90.

Exact Sciences Trading Up 0.1%

Exact Sciences stock traded up $0.03 during trading on Tuesday, hitting $56.97. The company had a trading volume of 219,074 shares, compared to its average volume of 2,594,935. The company's 50 day simple moving average is $46.58 and its 200-day simple moving average is $51.99. The stock has a market cap of $10.75 billion, a price-to-earnings ratio of -10.24 and a beta of 0.92. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 1-year low of $39.97 and a 1-year high of $72.83.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.16. The business had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company's quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.60) earnings per share. As a group, analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.